Mumbai, July 14 -- The move is aimed at realigning focus toward high-impact areas, including novel antibiotic drug discovery and biologics-led insulin solutions.

The decision comes after its US generics unit posted a $8 million loss in FY25. To facilitate the exit, Wockhardt filed for voluntary liquidation of its US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, under Chapter 7 of the US Bankruptcy Code, effective 11 July 2025.

The company says this decision enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas. The company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses ...